Kristen Quigley
Geschäftsführer bei MOLECULAR TEMPLATES, INC.
Aktive Positionen von Kristen Quigley
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
MOLECULAR TEMPLATES, INC. | Geschäftsführer | 02.08.2023 | - |
Corporate Officer/Principal | 01.01.2017 | 02.08.2023 |
Karriereverlauf von Kristen Quigley
Ehemalige bekannte Positionen von Kristen Quigley
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Geschäftsführer | - | - |
Ausbildung von Kristen Quigley
Washington University in St. Louis | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 4 |
Operativ
Chief Operating Officer | 2 |
Undergraduate Degree | 1 |
Corporate Officer/Principal | 1 |
Sektoral
Health Technology | 3 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
MOLECULAR TEMPLATES, INC. | Health Technology |
Private Unternehmen | 1 |
---|---|
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Health Technology |
- Börse
- Insiders
- Kristen Quigley
- Erfahrung